



Universiteit
Leiden
The Netherlands

Pharmacogenomics in drug development : implementation and application of PKPD model based approaches

Stringer, F.

Citation

Stringer, F. (2015, January 13). *Pharmacogenomics in drug development : implementation and application of PKPD model based approaches*. Retrieved from <https://hdl.handle.net/1887/31601>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/31601>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/31601> holds various files of this Leiden University dissertation.

Author: Stringer, Frances

Title: Pharmacogenomics in drug development : implementation and application of PKPD model based approaches

Issue Date: 2015-01-13

**Pharmacogenomics in Drug Development:
Implementation and Application of PKPD Model Based
Approaches**

Frances Stringer

**The publication of this thesis was financially supported by Takeda Development
Centre Europe Ltd, London, England**

Lay-out and printing by Ridderprint BV, Ridderkerk

© 2014. Copyright by F.Stringer

**Pharmacogenomics in Drug Development:
Implementation and Application of PKPD Model Based Approaches**

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker, volgens besluit
van het College voor Promoties
te verdedigen op dinsdag 13 januari 2014
klokke 11.15 uur

door

Frances Stringer

geboren te Durban in 1979

Promotiecommissie

Promotor:

Prof. Dr. M. Danhof

Co-Promotor:

Dr. J. de Jongh

Overige leden:

Prof. Dr. R.H.N. van Schaick, Erasmus MC Rotterdam

Prof. Dr. H.J. Guchelaar, LUMC

Prof. Dr. P.H. van der Graaf

Prof. Dr. J. Burggraaf, CHDR

Prof. Dr. B. van de Water

Table of Contents

Chapter 1.	Pharmacogenomics in Clinical Drug Development.....	7
Chapter 2.	PKPD Modeling of Pharmacogenomics in Early Drug Development. Scope and Motivation of the Investigations.....	35
Chapter 3.	The Effect of Genetic Polymorphisms in UGT2B15 on the Pharmacokinetic Profile of Sipoglitazar, a Novel Anti-diabetic Agent.....	49
Chapter 4.	Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist, Sipoglitazar.....	69
Chapter 5.	A Model-Based Approach to Analyze the Influence of UGT2B15 Polymorphism Driven Pharmacokinetic Differences on the Pharmacodynamic Response of the PPAR Agonist Sipoglitazar	103
Chapter 6.	Evaluation of the Long-term Durability and Glycemic Control of FPG and HbA1c for Pioglitazone in Japanese Patients with Type 2 Diabetes.....	139
Chapter 7.	Pharmacogenomics in Drug Development: Conclusions and Perspectives.....	173
	Summary in English	204
	Samenvatting in het Nederlands.....	211
	Curriculum Vitae	219
	List of Publications.....	220

